Effects of diltiazem alone and combined with mefruside on cardiovascular response at rest and during exercise, carbohydrate metabolism and serum lipoproteins in patients with systemic hypertension

Schulte, Karl-Ludwig; Meyer‐Sabellek, W.; Röcker, L.; Gotzen, R.; Distler, A.

doi:10.1016/0002-9149(87)91031-9

Cited by 10 publications

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Calcium Entry Blockers in the Treatment of Hypertension

Kaplan¹

1989

JAMA

View full text Add to dashboard Cite

Calcium entry blockers will be increasingly used for the treatment of hypertension. The currently available calcium entry blockers are similar in antihypertensive efficacy but differ in their effects on the atrioventricular node and the degree of peripheral vasodilatory action. The new generation of dihydropyridine calcium entry blockers exhibits more specific vasodilatory actions with a less negative inotropic effect, which may affect their use in patients with congestive heart failure. The responsiveness to these drugs is little affected by race or age. Because of their mild natriuretic action, the concomitant use of dietary sodium restriction or diuretics may be less necessary. Short-term administration of calcium entry blockers preserves or improves renal function; however, their long-term effect has not been documented. Calcium entry blockers have not exhibited protection against coronary heart disease, but experimental evidence supports the continued search for cardioprotection. Calcium entry blockers are important drugs for the treatment of hypertension; the second generation may provide additional benefits because of its more specific pharmacologic actions.

show abstract

Calcium Entry Blockers in the Treatment of Hypertension

Kaplan¹

1989

JAMA

View full text Add to dashboard Cite

show abstract

Cardiovascular Outcomes and Antihypertensive Drug Treatment in Older Women

2005

JAMA

View full text Add to dashboard Cite

Health Initiative Observational Study. We have a number of concerns that we believe limit drawing conclusions from this study. First, relative to the study sample size, the number of incident events was small and therefore the study may not have had adequate power to detect the end points in each subgroup (Tables 4 and 5 in the original article). For example, among women receiving a calcium channel blocker (CCB) plus an angiotensin-converting enzyme (ACE) inhibitor, only 8 cardiovascular deaths were reported. The P values for the overall comparison of therapies only reached borderline statistical significance for cardiovascular mortality, the outcome with the lowest annualized rates.Second, the confidence intervals reported for the hazard ratios in Tables 5 and 7 in the original article have not been adjusted for multiple comparisons, increasing the likelihood of a chance finding. Finally, the authors report the participants' use of antihypertensive medications at baseline and in year 3 of follow-up, but did not account for changes in antihypertensive medications that likely occurred over time.

show abstract